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Commentary
The paper by Keen and Keen [1] presents new estimates of
the absolute numbers of breast cancer deaths prevented
by mammographic screening. The estimation is carried
out by synthesis of a range of estimates of relative risk of
breast cancer mortality loosely derived from the ran-
domised trials, SEER data on breast cancer mortality and
the proportion of the recent reduction in breast cancer
mortality estimated by Berry et al to be owing to mam-
mography [2]. Much is made of the relatively small abso-
lute benefit estimated, and indeed the absolute benefit
estimated here is notably smaller than that estimated in a
randomised trial, and in an evaluation of service screening
[3,4]. In relation to the results and the accompanying dis-
cussion, two remarks spring to mind.
The first is that the paper rather labours the obvious point
that in breast cancer screening, as in primary and second-
ary prevention generally, one has to apply the interven-
tion to large numbers of healthy subjects in order to
benefit the few who are unlucky enough to develop the
disease. The same argument can be made of vaccination,
cervical screening and many other interventions. If one is
in the business of preventive medicine, one has to accept
this as a fact of life. The improvements in length of life in
recent decades are a combination of two per thousand
from one disease, three per thousand from another, and
so on.
The second point is that the accuracy of the figures arrived
at is questionable. From a rather convoluted ecological
synthesis of information from different sources, the
authors arrive at the finding that 1.8 breast cancer deaths
would be prevented by repeatedly screening 1000 women
for 15 years. Directly estimating this from empirical ran-
domised trial data gives a figure of approximately 3 per
1000 over ten years [3], and from service screening in Swe-
den 2.1 per 1,000 [4]. They also estimate that less than 5%
of screen-detected cases have their lives saved as a result of
the screening. This is clearly at odds with the experimental
evidence. In the Swedish Two-County Trial, 141 breast
cancer deaths were prevented, 15% of the 928 screen-
detected cancers.
Why are the authors' modelled results different from the
empirically observed results of others? One reason may be
the difference between the time frames of the authors'
model and the period of observation in the empirical
data. Another may be their underestimation of the relative
benefit of screening. The randomised trials combined
yield an estimate of a 20% mortality reduction with invi-
tation to screening [5], whereas the authors posit this as
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the reduction conferred by actually receiving screening. A
more subtle reason may be the authors' procedure of first
removing the deaths from breast cancer estimated to be
prevented by innovations in therapy, then applying the
relative reduction from screening to the remaining deaths.
The latter was estimated using all tumours in the trials,
not just for whom death had not been prevented by spe-
cific treatments. The relative mortality reduction from
mammography in the subgroup of cases whose lives are
not saved as a result of treatment is likely to be considera-
bly larger than the overall estimated reduction.
In any case, whatever the reason for the differences, when
there is a disagreement between direct results from empir-
ical data and modelled estimates derived by combining
information from disparate sources, it would be wise to
trust the former.
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